The nation of Zimbabwe has rejected a substantial US health deal worth $367m (£272m) spanning five years due to the United States' insistence on confidential information.
This move was revealed after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson later stated that the United States was seeking biological samples for scientific study and commercial purposes while refused to share the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for more talks to secure a agreement acceptable to both sides so the country's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court suspended a similar health funding agreement after legal challenges were raised about the safety of citizens' health data.
After resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed aid for the American government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government agreements to boost openness and responsibility.
According to reports, 16 African countries have to date signed similar health pacts, representing more than $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, with no equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for medical research without any certainty that the end products would be accessible to our people if a new pandemic arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining structures already set up via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to manage potential global health emergencies.
"This system is intended to guarantee that when a nation provides its information, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage further dialogue with our US partners on how subsequent co-operation could be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but urged that talks should continue given that a large portion of the country's HIV programmes were funded by foreign aid.
"Where specific concerns exist, such as those relating to data governance or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," it added.
The halted deal emphasises the continuing challenges between receiving crucial international aid and protecting a country's data in an increasingly interconnected world.